Stanford Spinout Eiger Biopharma Licenses Hep C Drug Targets from School

Genomeweb.com reports that Eiger Biopharmaceuticals, a recent spinout of Stanford University, said last week that it has licensed the exclusive rights to a hepatitis C virus technology from the university.

"Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors," David Cory, president and CEO of Eiger, said in a statement.

"We are rapidly advancing novel small-molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients," Cory added.

With the exclusive rights from Eiger Biopharmaceuticals, will we see others clamoring to come up with hepititis biopharmaceuticals?

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |